23 May 2013
Keywords: positve, data, targeted, genetics, tgaac95, firm, presented
Article | 12 June 2006
US firm Targeted Genetics has presented interim data from its ongoing Phase I/II trial of tgAAC94 in patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 June 2006
22 May 2013
© 2013 thepharmaletter.com